C12N 2800/80
Vectors containing sites for inducing double-stranded breaks
Official title: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
C12N2800/80 (Vectors containing sites for inducing double-stranded breaks) appears on 1,150 US grants and 2,569 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,150
- Published applications
- 2,569
- Assignees
- 712
- Inventors
- 3,874
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 2 |
| 2003 | 0 | 5 |
| 2004 | 0 | 6 |
| 2005 | 1 | 4 |
| 2006 | 3 | 3 |
| 2007 | 0 | 2 |
| 2008 | 2 | 1 |
| 2009 | 1 | 3 |
| 2010 | 1 | 9 |
| 2011 | 3 | 35 |
| 2012 | 2 | 19 |
| 2013 | 6 | 10 |
| 2014 | 10 | 23 |
| 2015 | 8 | 27 |
| 2016 | 20 | 79 |
| 2017 | 19 | 47 |
| 2018 | 26 | 127 |
| 2019 | 54 | 240 |
| 2020 | 94 | 326 |
| 2021 | 121 | 346 |
| 2022 | 156 | 329 |
| 2023 | 156 | 366 |
| 2024 | 174 | 314 |
| 2025 | 187 | 156 |
| 2026 | 105 | 90 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- RNA guide genome editing in citrus using CRISPR-ribonucleoprotein complexes6 Oct 2026US 12,753,413 B2University of Florida Research Foundation, Inc.
- Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene29 Sep 2026US 12,747,430 B2Precision BioSciences, Inc.
- Modulating human Cas9-specific host immune response29 Sep 2026US 12,747,432 B2Arizona Board of Regents on behalf of Arizona State University
- Methods of treating rheumatoid arthritis using RNA-guided genome editing of HLA gene22 Sep 2026US 12,742,179 B2National Jewish Health
- Method for producing genetically edited birds having resistance to avian influenza viruses22 Sep 2026US 12,742,180 B2Seoul National University R&Db Foundation
- Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene8 Oct 2026US 2026/0308549 A1Precision BioSciences, Inc.
- Crispr-cas genome engineering via a modular aav delivery system8 Oct 2026US 2026/0308630 A1The Regents of the University of California
- Compositions, systems and methods for programming immune cell function through targeted gene regulation1 Oct 2026US 2026/0297545 A1Duke University
- Intraluminal stents for treating benign prostatic hyperplasia1 Oct 2026US 2026/0297612 A1Rivermark Medical, Inc.
- CRISPR-Cas9 Knock-out of SHP-1/2 to Reduce T cell Exhaustion in Adoptive Cell Therapy24 Sep 2026US 2026/0286300 A1The Trustees of the University of Pennsylvania
Most cited
By later US patents
- CRISPR-Cas systems and methods for altering expression of gene products1,186US 8,697,359 B1Massachusetts Institute of Technology · 2014
- CRISPR-Cas systems and methods for altering expression of gene products483US 8,945,839 B2Massachusetts Institute of Technology · 2015
- CRISPR-Cas systems and methods for altering expression of gene products470US 8,771,945 B1Massachusetts Institute of Technology · 2014
- RNA-guided human genome engineering263US 9,023,649 B2President and Fellows of Harvard College · 2015
- Nucleic acid-guided nucleases247US 9,982,279 B1Inscripta, Inc. · 2018